Healthcare / BiotechnologyTokyo
$581.00
-18.00 (-2.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.3B · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-51.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.21B · FCF $-1.28B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $108.9M |
| Net Income | $-1.21B | $-1.21B | $-1.24B | $-855.6M | $-531.0M |
| EBITDA | $-1.26B | $-1.26B | $-1.24B | $-848.6M | $-522.3M |
| EPS | -67.90 | -67.90 | -83.03 | -88.31 | — |
| Operating Margin | — | — | — | — | -502.7% |
| Net Margin | — | — | — | — | -487.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 1.47 | 1.71 |
| Current Ratio | 15.98 | 15.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.28B | $-1.28B | $-1.40B | $-719.8M | $-688.6M |
| Returns | |||||
| ROE | -51.7% | -51.7% | -64.4% | -341.3% | -121.2% |
| Valuation | |||||
| P/B | 4.42 | 4.42 | 8.27 | 28.56 | 7.86 |
| Growth & Yield | |||||
| EPS Growth | 18.2% | 18.2% | 6.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-52.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-83.03 → -67.90
Residual
-52.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.